Ranibizumab Versus Dexamethasone Implant in Diabetic Macular Edema

G. d'Annunzio University40 enrolled

Overview

Between December 2016 and June 2017 a total of 40 eyes from 40 diabetic retinopathy patients with diabetic macular edema were recruited at the Ophthalmologic Clinic of University "G. d'Annunzio", Chieti-Pescara, Italy.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Diabetic Macular Edema

Interventions

Dexamethasone intravitreal implant 0.7 mgDRUG

Intravitreal Implant of dexamethasone

Ranibizumab InjectionDRUG

Injection of ranibizumab

Eligibility

Sex: ALLMin age: 19 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age \>18 years old * BCVA greater than 0.5 LogMAR in the study eye at baseline examination * Presence of recent DME * CMT \> 300µm as measured using the SD-OCT at the baseline examination Exclusion Criteria: * Any previous ocular surgery in the last 6 months * Laser treatments * Prior ocular trauma * Retinal vascular diseases * Vitreo-retinal interface diseases * Medium lens opacities (according to Lens Opacities Classification System)

Outcomes

Primary Outcomes

Central macular thickness

Decrease of macular thickness

Time frame: 6 months

Secondary Outcomes

visual acuity

Increase of mean visual acuity

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.